Company Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Ratings for Celltrion, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
172,900 ^KRW	-2.37%		-5.10%	-14.19%

Apr. 17	Celltrion, Inc. announces an Equity Buyback for 436,047 shares.	CI
Apr. 17	Celltrion, Inc. authorizes a Buyback Plan.	CI

Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.

Number of employees: 2,034

KRW in Million	2022	Weight	2023	Weight	Delta
Biopharmaceutical 86.1 %	1,937,469	84.8 %	1,873,430	86.1 %	-3.31%
Chemical Drugs 23.0 %	653,519	28.6 %	500,777	23.0 %	-23.37%
Reconciling Items -9.3 %	-310,898	-13.6 %	-202,919	-9.3 %	-34.73%
Others 0.2 %	3,877	0.2 %	5,143	0.2 %	+32.66%

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 97.1 %	2,090,465	91.5 %	2,113,156	97.1 %	+1.09%
Asia 2.9 %	62,069	2.7 %	63,275	2.9 %	+1.94%

Managers	Title	Age	Since
Wu-Sung Ki CEO	Chief Executive Officer	62	07-04-23
Ho-Seop Lee DFI	Director of Finance/CFO	49	-
Jung-Jin Seo CHM	Chairman	66	-
Sung-Han Lee CMP	Compliance Officer	42	-
Yoon-Mo Koo PRN	Corporate Officer/Principal	54	-
Sang-Joon Lee PRN	Corporate Officer/Principal	57	-
Shin-Jae Jang PRN	Corporate Officer/Principal	60	-
Jung-Won Yoon PRN	Corporate Officer/Principal	57	-

Members of the board	Title	Age	Since
Soon-Woo Lee BRD	Director/Board Member	73	-
Jung-Jin Seo CHM	Chairman	66	-
Jae-Sik Lee BRD	Director/Board Member	66	-
Dong-Il Kim BRD	Director/Board Member	65	08-07-16
Joseph Lee BRD	Director/Board Member	66	08-07-16
Wu-Sung Ki CEO	Chief Executive Officer	62	07-04-23
Geun-Young Kim BRD	Director/Board Member	64	-
Dae-Hyeon Yoo BRD	Director/Board Member	65	-
Hyeok-Jae Lee BRD	Director/Board Member	48	-
Young-Hye Ko BRD	Director/Board Member	69	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	225,966,951	143,865,451 ( 63.67 %)	13,082,991 ( 5.790 %)	63.67 %

Name	Equities	%	Valuation
Jung-Jin Seo 27.52 %	60,008,150	27.52 %	8 523 M ₩
National Pension Service of Korea 5.275 %	11,502,033	5.275 %	1 634 M ₩
Temasek Holdings Pte Ltd. (Investment Management) 2.533 %	5,523,531	2.533 %	784 M ₩
CELLTRION, INC. 2.067 %	4,508,124	2.067 %	640 M ₩
Celltrion Inc. Employee Stock Ownership ASSN. 0.2461 %	536,669	0.2461 %	76 M ₩
Sjunde AP-fonden 0.1503 %	327,635	0.1503 %	47 M ₩
State Street Global Advisors Ltd. 0.1390 %	303,093	0.1390 %	43 M ₩
Heon-Yeong Yu 0.1148 %	250,384	0.1148 %	36 M ₩
Hyung-Ki Kim 0.0943 %	205,618	0.0943 %	29 M ₩
Northern Trust Fund Managers (Ireland) Ltd. 0.0687 %	149,867	0.0687 %	21 M ₩

Name	Equities	%	Valuation
CELLTRION PHARM, INC. 54.81%	22,797,613	54.81%	1,779,780,238 $
CELLTRION, INC. 2.07%	4,508,124	2.07%	640,262,434 $
BIOTOXTECH CO., LTD. 10.22%	1,631,134	10.22%	7,269,671 $

Celltrion, Inc.

23 Academy-ro Yeonsu-gu

22014, Inchon

http://www.celltrion.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

172,900 KRW

Average target price

227,765 KRW

Spread / Average Target

+31.73%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
CELLTRION, INC.	-14.19%	26.67B
IQVIA HOLDINGS INC.	-1.42%	41.35B
LONZA GROUP AG	+42.15%	40.38B
MODERNA, INC.	+1.97%	39.05B
ICON PUBLIC LIMITED COMPANY	+1.82%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.55%	18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.07%	11.68B
MEDPACE HOLDINGS, INC.	+21.36%	11.6B
UNITED THERAPEUTICS CORPORATION	+8.20%	11.15B
BIO-TECHNE CORPORATION	-19.49%	9.78B

Other Biotechnology & Medical Research